Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine

By sjmartinez • April 27, 2023

Hendershot A, Slabaugh M, Riaz KM, Moore KN, O'Malley DM, Matulonis U, Konecny GE. Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine. Gynecol Oncol Rep. 2023 Feb 28;47:101155. doi: 10.1016/j.gore.2023.101155. PMID: 37102083; PMCID: PMC10123335.

Tags: Antibody-drug conjugates, Eye care, Folate receptor alpha, Hematology/Oncology, Mirvetuximab soravtansine, Ocular adverse events, ovarian cancer, Publications

Related Posts

Blinatumomab Nonresponse Correlates with Poor Survival After Brexucabtagene

Srinagesh HK, Gupta VK, Zhang A, Grunwald MR, Connor MP, Kota VK, Boccucci J, Ulrickson ML, Pradeep R, Hill LC, Tsai SB, O'Connor TE, Sandhu[...]

Neoadjuvant Stereotactic Body vs. Conventionally Fractionated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Propensity Score-Matched Analysis

Shimizu T, Zheng S, Maeda S, Link J, Deranteriassian A, Premji A, King J, Girgis M, Hines OJ, Wainberg Z, Raldow A, He J, Burns[...]

Author Correction: Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis

Li S, Noor ZS, Zeng W, Stackpole ML, Ni X, Zhou Y, Yuan Z, Wong WH, Agopian VG, Dubinett SM, Alber F, Li W, Garon[...]